AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (418.1 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Perspective | Open Access

Toward the precision use of Chinese PARP inhibitors in ovarian cancer: clinical progress, resistance mechanisms, and future perspectives

Jing Yu1,2,*, Maochen Li3,*, Yuhan Zhu2, Shengnan Wang2, Yuzhao Jiang1, Wei Cui1 ( ), Lingying Wu2 ( )
Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China

*These authors contributed equally to this work.

Show Author Information

References

【1】
【1】
 
 
Crossref Google Scholar
Cancer Biology & Medicine
Volume 23 Issue 6,
June 2026
Pages 788-795
DOI: 10.20892/j.issn.2095-3941.2026.0102

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Yu J, Li M, Zhu Y, et al. Toward the precision use of Chinese PARP inhibitors in ovarian cancer: clinical progress, resistance mechanisms, and future perspectives. Cancer Biology & Medicine, 2026, 23(6): 788-795. https://doi.org/10.20892/j.issn.2095-3941.2026.0102

9

Views

0

Downloads

0

Crossref

0

Web of Science

0

Scopus
Received: 02 February 2026
Accepted: 21 April 2026
Published: 01 June 2026
©2026 The Authors.

Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)